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Introduction
Nationwide, clinical trial enrollment is very low for eligible patients, averaging 3-5%, 
and this has a significant impact on both patient’s health as well as medical research 
outcomes. The current paradigm is more focused enrollment of historically 
underrepresented groups, however, additional research is directed at potential clinic 
based solutions for how to more effectively recruit all patients. Studies are showing 
improved clinical efficiency when using medical scribes (Gidwani et al., 2017) as well 
as using artificial intelligence software to screen for eligible patients (Calaprice-Whitty 
el al., 2019). Jefferson’s Otolaryngology department has recently transitioned to full-
time scribe coverage for the Head and Neck cancer clinics in addition to increased 
patient volume over the past few years and is interested in determining what methods, 
if any, may be effective ways to enroll more patients on clinical trials. We are 
interested in exploring issues with recruitment from the patient and clinician 





• Research Question 
– What are possible barriers to enrollment from the 
perspective of both surgical oncologists and their 
patients? 
• Hypothesis  
– Use of an Epic SmartPhrase for evaluation of common 
barriers to clinical trial enrollment will allow further 
documentation for explanations of ineligibility or refusal 
to enroll. 
– Additionally, we anticipate that lowered wait times will 
lead to increased patient enrollment into clinical trials 
Approach & Results
• Study design: Prospective Observational 
• Population / study sample: Patients who were eligible for 
any of the 8 clinical trials for H&N cancer offered at 
Jefferson between August and December 2020 were 
identified. 
• Intervention: Pending, but a video to be played in the 
clinic waiting room with basic information regarding 
clinical trial enrollment.   
• Data source and collection: Epic EMR and REDCap 
• Rationale for Approach: We utilized an Epic EMR phrase 
to capture if a trial was offered or not and why, whether a 
patient refused enrollment and why, and patient wait time. 

                     Approach & Results
During the 4 month period, the clinic saw 45 new patients with a 
cancer diagnosis and the EMR SmartPhrase was used 32 times. 
For those offered a trial, 38.5% agreed to enroll and 15.3% 
deferred to make a final decision at a later appointment. Of 
patients that were eligible for a trial but declined, 60% were due 
to concerns about clinical trial enrollment and 40% because of 
general disinterest. Reasons for ineligibility were more difficult to 
track in the group where SmartPhrase was not used because the 
providers’ thought processes were not declared. We will present 
average wait time data at a later time.







Said No 5 Nivo + IDO trial and ETIP trial 
were the two most commonly 
enrolled trials
Conclusions
• Our preliminary data shows an increased rate of patient 
enrollment (38.5%) into clinical trials compared to the 
national average (3-5%) 
• Likely this percentage will fall with increased patient 
volume but could be lower due to concerns about COVID  
• Standardizing clinic note templates with the Epic 
SmartPhrase likely leads to increased patient enrollment 
• Consistent usage of SmartPhrase was complicated by 
scribe and departmental turnover during the 4 month 
period 
• We are awaiting data regarding patient wait times, which 
may pose a major barrier in enrollment
Future Directions
We are currently designing the intervention, which is a 
video with basic information and FAQ’s regarding clinical 
trials, featuring the surgical and medical oncologists as well 
as the clinical trial coordinator for the cancer center. This 
will be shown in the waiting room of the clinic on repeat so 
that new patients are more comfortable with the topic of 
clinical trials before they are approached about it by the 
surgeons. By time of implementation, we will have 
approximately 6 months of pre-intervention data.
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